Follow

Submissions from 2015

PDF

Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus, C. Aranow, D. L. Kamen, M. Dall'Era, E. M. Massarotti, M. C. Mackay, F. Koumpouras, A. Coca, W. W. Chatham, M. E. Clowse, L. G. Criscione-Schreiber, S. Callahan, E. A. Goldmuntz, L. Keyes-Elstein, M. Oswald, P. K. Gregersen, and B. Diamond

Link

A Note from the Editor-in-Chief, Deputy Editor, and Managing Editor, V. R. Bonagura, J. L. Casanova, and D. W. Rosenthal

PDF

Selective Impairment of Spatial Cognition Caused by Autoantibodies to the N-Methyl-d-Aspartate Receptor, E. H. Chang, B. T. Volpe, M. Mackay, C. Aranow, C. Kowal, P. Mattis, R. Berlin, S. Mader, T. S. Huerta, P. T. Huerta, B. Diamond, and +3 additional authors

Link

Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials Lessons Learned from the Euro-Lupus Nephritis Cohort, M. Dall'Era, M. G. Cisternas, D. E. Smilek, L. Straub, F. A. Houssiau, R. Cervera, B. H. Rovin, and M. Mackay

Link

Human Radiation Dosimetry for the N-Methyl-D-Aspartate Receptor Radioligand C-11-CNS5161, V. Dhawan, W. Robeson, D. Bjelke, T. Chaly, K. Graf, M. Hellman, L. M. Zhuo, M. Mackay, and D. Eidelberg

PDF

Reply to: Nasal endoscopy to characterize sinonasal disease, A. E. Dixon, M. Castro, R. I. Cohen, L. B. Gerald, J. T. Holbrook, C. G. Irvin, S. Mohapatra, S. P. Peters, S. Rayapudi, R. A. Wise, and +1 additional author

Link

Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus, M. Mackay

PDF

Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus, M. Mackay, C. C. Tang, B. T. Volpe, C. Aranow, P. J. Mattis, R. A. Korff, B. Diamond, and D. Eidelberg

PDF

Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort, B. Parker, M. B. Urowitz, D. D. Gladman, M. Lunt, R. Donn, S. C. Bae, J. Sanchez-Guerrero, C. Aranow, M. Mackay, I. N. Bruce, and +30 additional authors

PDF

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial, F. Tamirou, B. R. Lauwerys, M. Dall'Era, M. Mackay, B. Rovin, R. Cervera, F. A. Houssiau, D. Abramowicz, L. de Bruxelles, R. Westhovens, and +35 additional authors

Submissions from 2014

PDF

Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study, A. Askanase, M. Byron, L. Keyes-Elstein, P. Cagnoli, J. McCune, B. Diamond, D. Daikh, A. Davidson, M. Mackay, D. Wofsy, and +24 additional authors

PDF

Treatment of Lupus Nephritis With Abatacept, A. D. Askanase, M. Byron, L. L. Keyes-Elstein, P. C. Cagnoli, W. J. McCune, W. W. Chatham, A. Davidson, B. Diamond, M. Mackay, R. Winchester, and +24 additional authors

PDF

X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including Pneumocystis jirovecii, A. M. Jongco, J. D. Gough, K. Sarnataro, D. W. Rosenthal, J. Moreau, P. Ponda, and V. R. Bonagura

Link

Rituximab and immune deficiency: case series and review of the literature, B. Kaplan, Y. Kopyltsova, A. Khokhar, F. Lam, and V. Bonagura